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Continuous ambulatory peritoneal dialysis and hemodialysis: Compar-
ison of patient mortality with adjustment for comorbid conditions. A
historical prospective national sample of 1,725 diabetic and 2,411
non.diabetic Medicare end.stage renal disease (ESRD) patients incident
from 1986 to 1987 was analyzed for the mortality of patients selected to
receive continuous ambulatory peritoneal dialysis (CAPD) or hemodi-
alysis (HD) with adjustment for patient characteristics, including the
presence of comorbid conditions at onset of ESRD. Cox proportional
hazards analyses were used to compare the mortality of CAPD and HD
patients. Patients were followed from 30 days following onset of ESRD
until two to four years post-onset. No statistically significant difference
in relative mortality risk (RR) was found among non-diabetic patients
selected for CAPD compared to HD (RR = 0.84 for CAPD versus I-ID,
P = 0.25), while evidence of higher adjusted mortality for CAPD
compared to HD was found among diabetic patients (RR = 1.26, P =
0.03). Mortality analyses adjusted for pre-treatment risk factors suggest
that CAPD and HD provide incident non-diabetic ESRD patients with
similar expected survival outcomes. Evidence that increased mortality
was associated with CAPD among diabetic patients, particularly among
elderly patients, suggests the need for further controlled studies of
mortality among CAPD patients with diabetes.
During 1990 the number of people beginning treatment for
end-stage kidney failure under the Medicare ESRD program in
the U.S. was over 45,000, a number that increased by 8 to 11%
per year between 1986 and 1990 [1]. For the increasing numbers
of ESRD patients requiring maintenance therapy each year,
treatment with renal transplantation has become limited by the
availability of organs, resulting in waiting times for transplants
typically exceeding one year. The two primary dialysis treat-
ment options include hemodialysis and continuous ambulatory
peritoneal dialysis (CAPD), which combined were used to treat
92% of dialysis patients and 68% of ESRD patients prevalent in
1990 [11. The selection of an appropriate dialytic therapy is
influenced by many factors, including the expected survival
outcome for each patient, given individual characteristics and
an associated level of pre-treatment mortality risk.
Received for publication April 2, 1993
and in revised form October 28, 1993
Accepted for publication October 28, 1993
© 1994 by the International Society of Nephrology
Several previous studies of incident (new) ESRD patients
have demonstrated that the process of selecting dialysis modal-
ity is not random [2—6]. Overall patterns in the selection of
patients to CAPD as opposed to HD have revealed differences
in the level of comorbidity between patients receiving CAPD
and those receiving HD, with statistical adjustment for age,
race, and diabetes [2]. Further, many of the individual comor-
bid conditions shown to influence selection of therapy were
associated with increased mortality in a prior analysis of HD
patients [7]. Studies that compare patient outcomes by treat-
ment modality without adjusting for comorbidity may incor-
rectly attribute differences in mortality to differences in the
quality of treatment.
This study compares patient survival outcomes for a large
national randomly selected sample of 1986 to 1987 incident
ESRD patients receiving CAPD or HD at thirty days following
onset of ESRD. All comparisons of patient mortality and
survival between CAPD and HD have been adjusted for an
extensive set of patient risk factors, including the presence of
comorbid conditions within ten years prior to reaching end-
stage kidney failure.
Methods
Data collection
The origin of most of the data used in these analyses is the
Case Mix Severity Special Study of the United States Renal
Data System (USRDS). These data were abstracted from pa-
tient medical records by the 18 ESRD Networks under contract
with the Health Care Financing Administration (HCFA) using a
data collection form developed and tested by the USRDS
Coordinating Center, the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK), and HCFA [8]. The
data were abstracted during 1989 for a sample of 4,892 patients
who started dialysis therapy for ESRD during 1986 to 1987. All
patients in the study were Medicare-entitled for dialysis ser-
vices within 90 days following onset of ESRD. Patients were
selected using a national randomized two-stage cluster sampling
process. ESRD patients incident in the U.S. during 1986 to 1987
were selected at random (from 291 dialysis units also selected at
random) according to the last two digits of their social security
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numbers. To facilitate data abstraction, the sample design was
limited geographically to those dialysis units within one day's
travel of one of 18 ESRD Network Offices in the United States.
Among the data collected were patient identifiers, informa-
tion on health insurance, the presence or absence of a variety of
comorbid conditions within ten years prior to diagnosis of
ESRD, physical characteristics (patient height, weight, nutri-
tional status, blood pressure) measured within two to six weeks
of ESRD onset, dialysis treatment modality, prescribed dose of
dialysis, date of transplant (for censoring), psychosocial status
at onset of ESRD, and ESRD-related laboratory data. A copy of
the data abstraction form used to collect data for this study was
published in Appendix B of the USRDS 1992 Annual Data
Report [4].
The data collected on the abstraction form were supple-
mented with data from the USRDS database, which contains
longitudinal data on all Medicare ESRD patients in the United
States from 1977 to the present [8]. Most of these data are
derived from the HCFA Program Management and Medical
Information System [81. The supplemental data used in this
analysis, including the date of first dialysis service and the date
and type of changes in dialysis treatment modality, were not
collected during data abstraction. USRDS data were based on a
March 31, 1991 update of HCFA file sources, which were used
to determine survival and transplant status as of April 1, 1990.
Analytical methods
This analysis compared survival outcomes for new ESRD
patients selected to the CAPD and HD patient groups after
adjusting for differences in socio-demographic factors (age, sex,
race, primary cause of ESRD) and other indicaLors of case mix
severity (comorbid conditions before onset of ESRD). Patients
were assigned to a modality group based on the method of
treatment they were receiving at one month after reported onset
of ESRD. Modality classifications included CAPD, continuous
cycling peritoneal dialysis (CCPD), and hemodialysis (HD),
performed in-center or at home. Patients receiving intermittent
peritoneal dialysis, dialysis of an unknown type, or who had a
functioning graft at one month post-ESRD were excluded from
this study. Patients less than 15 years old at onset of ESRD
were also excluded from these analyses since selection of a
treatment modality for younger children involves many consid-
erations that do not apply to older patients.
Given the broad clinical differences between diabetic and
non-diabetic patients, analyses of patient mortality were per-
formed separately according to the presence of diabetes. Two
sources were used to classify patients as diabetic: (1) the
USRDS database, which indicated the primary cause of ESRD
as diabetic nephropathy; and (2) the Case Mix Severity Study
data collection form, which was used to indicate a history of
diabetes within ten years of onset of ESRD. All diabetic
patients were combined into a single category, regardless of the
type or duration of diabetes prior to onset of ESRD.
The expected mortality effects of differences in selection
according to patient characteristics, specifically age, race, and
diagnosis, were evaluated using results from previous research.
This was done by weighting previous estimates of the risk ratio
for each characteristic by the proportion of patients with that
characteristic in the current study. The result was expressed for
CAPD relative to HD. For example, diabetic patients, selected
with greater frequency for CAPD (45.5% DM) than for HD
(40.9% DM) in the current study, have been shown to be at
higher risk of death [9—12] than non-diabetic patients (RR =
1.9), yielding slightly higher expected mortality for patients
selected for CAPD, independent of other factors: [0.455*1.9 +
0.545*l]/[0.409*l.9 + 0.591*11, or RR = 1.03.
Analyses of patient mortality adjusted for patient character-
istics and comorbid conditions employed Cox proportional
hazards regression techniques [13]. To allow for a delay in the
reporting of death data, follow-up was stopped on April 1, 1990,
yielding a follow-up period of 2.25 to 4.25 years for each
patient. Patients were censored (that is, removed from the
analysis) 30 days after the first change in dialysis modality
(modality history model) to attribute time at risk and any deaths
during the initial 30 days following the first modality change to
the original modality. The dependent variable used in propor-
tional hazards analyses measured the time in days from onset of
ESRD to the earliest of death, transplant, 30 days after the first
modality change, or April 1, 1990. Only patients surviving at
least 90 days following onset of ESRD were considered.
The primary Cox proportional hazards model included age at
onset of ESRD, race (black, white, other), gender, modality
type (HD, CAPD, CCPD), and several indicators of comorbid-
ity at time of ESRD. The measured comorbid conditions
included the presence or absence of coronary heart disease,
congestive heart failure, cerebrovascular accident, peripheral
vascular disease, neoplasm, smoking status, obesity, and inabil-
ity to ambulate, eat, or transfer. A comprehensive list of the 25
individual comorbid conditions for which information was
collected was reported in a previous analysis [21. Other indica-
tors of patient condition included serum albumin, modeled as a
series of binary variables (0—2.4, 2.5—2.9, 3.0—3.4, 3.5—3.9, and
4.0 gldl) to allow for non-linear effects of serum albumin on
mortality, and systolic blood pressure (<120, 120—159, 160—199,
and 200 mm Hg).
An age-by-modality interaction term was also included in the
primary model to consider the hypothesis that comparisons of
mortality between CAPD and HD vary by age [3]. In defining
this interaction term, the mean age of all HD patients was
subtracted from the age of each patient to allow the relative
mortality risk for CAPD versus HD to be evaluated for the
average aged patient. Similarly, an age-by-race interaction term
was included in the model to adjust for the effect of age on
mortality comparisons by race, since lower mortality among
blacks relative to whites becomes accentuated as age increases
[8]. Other covariates included pre-dialysis blood urea nitrogen
(BUN) and creatinine values.
For patients lacking information for one or more covariates,
numeric variables (such as, serum albumin) with missing values
were set to the mean value across all non-missing observations
in each diabetes subgroup, while categorical measures of co-
morbidity with missing values were set to zero (such as,
comorbid condition not present). This was done to avoid the
exclusion of these patients from the proportional hazards model
due to small amounts of missing data. A generic "missing case
mix data" variable was then defined to identify those patients
lacking information for one or more covariates and was in-
cluded in the model to account for potentially different mortal-
ity among subjects with missing data.
Stratified Cox proportional hazards models were used to
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Table 1. Incident Medicare ESRD patient characteristics for CAPD
and HD, 1986 to 1987C
Patient
characteristic
HD
(N = 3,376)
CAPD
(N = 681)
Age mean 58.7 53.7
Black % 36.7 27.0
Female % 48.1 4.3
Diabetes %
Primary Dx 28,1 36.4
Any prior HXb 40.9 45.5
a Patients surviving <90 days were excludedb Includes patients with diabetes as primary Dx in previous row
generate survival estimates for CAPD and HD, separately for
diabetic and non-diabetic patients. Adjusted survival curves
were calculated for CAPD and HD patients at the mean value
for each of the patient covariates, for each diabetes subgroup.
Survival estimates were therefore adjusted for the distribution
of patient characteristics and comorbid conditions specific to
diabetic and non-diabetic patients. To test the assumption of
proportionality between the hazard functions for CAPD and
HD, several tests were employed: (1) stratified adjusted sur-
vival curves were used to compute log[—log(survival)]; (2) a
time dependent factor was modeled in a separate Cox analysis;
and (3) the primary Cox model was re-estimated with all
patients censored at one year of follow-up, with subsequent
follow-up treated as a separate observation. This final model
was stratified using a binary variable that identified observa-
tions for CAPD patients treated more than one year. The same
binary variable was then included as a covariate in the propor-
tional hazards model to isolate mortality effects observed for
CAPD patients after one year of follow-up.
Several supplementary proportional hazards models were
considered in sensitivity analyses. Two separate models for
diabetic patients included covariates measuring the duration
and severity of diabetes as reported on the data abstraction
form [8]. The first model included a covariate for the duration of
diabetes in years prior to onset of ESRD, with adjustment for
pre-treatment risk factors. A separate model, also for diabetic
patients only, included a covariate for patients with a prior
history of diabetes but with a diagnosis other than diabetes
identified as the primary cause of ESRD.
An alternate proportional hazards specification included a
covariate for undernourished patients to measure effects of
nutrition on mortality, independent of serum albumin and
serum creatinine. A third set of models analyzed the interaction
between age and treatment modality by examining the relative
mortality risk for CAPD compared to HD separately for two
broadly defined groups of younger and older patients (<50, 50
years at ESRD onset). An additional set of proportional hazards
models evaluated CAPD and HD mortality risk without assum-
ing proportionality in the hazard functions for CAPD and HD
over time. This set of models was designed to test the null
hypothesis that the relative risk of death for CAPD relative to
HD was not different in the short term (that is, first year of
treatment) from the longer term (after the first year of treat-
ment).
Table 2. Relative chancea of selected comorbid conditions being
present at onset of ESRD for CAPD compared to HD, with
adjustment for age and diabetes, 1986 to 1987 incident Medicare
patients (N = 4,057)
Comorbid
Relative chance, adjustedb
CAPD
condition Unadjusted Hemodialysis Relative
at onset of ESRD % Present (reference) chance PC
Congestive heart 40.3 1.00 0.92 0.09
failure
Coronary heart
diseased
40.4 1.00 0.97 0.49
Cerebrovascular 10.1 1.00 0.75 0.03
accident
Peripheral vascular 19.3 1.00 1.23 <0.01
disease (PVD)C
Amputation due to 4.6 1.00 0.74 0.13
PVD
Unable to walk 2.3 1.00 0.56 <0.01
independently
a Analysis excludes patients treated with CCPD and differs slightly
from previous results for CAPD/CCPD in reference 2b Adjusted for age and diabetes
The statistical signfficance of relative risk values comparing CAPD
to HD was estimated using Cochran-Mantel-Haenszel statistics
d Includes coronary heart disease, bypass surgery, coronary angio-
plasty, and abnormal angiograph
Includes amputation due to PVD, absent foot pulses, and claudica-
tion
Results
Sample description
Table 1 indicates that patients selected for HD were on
average older and more likely black and non-diabetic than
patients selected for CAPD. When adjusting for the two major
factors of age and diabetes status, CAPD patients (relative to
HD patients) were less likely to have a cerebrovascular acci-
dent and were more likely to have peripheral vascular disease
and to be ambulating independently (Table 2). Patients receiv-
ing a first kidney transplant during the follow-up period were 9
and 7% for diabetic CAPD and HD patients, respectively, and
8 and 11% for non-diabetic CAPD and HD patients.
Relative mortality risk
Adjusted relative mortality risks associated with selected
patient characteristics, including comorbid conditions, are re-
ported separately in Table 3 for 1,725 diabetic and 2,411
non-diabetic patients. For each patient characteristic, mortality
estimates are expressed relative to a selected reference group,
which is assigned a mortality risk of 1.00; any deviation from
1.00 suggests an estimated relative risk (RR) that is increased (if
RR> 1.00) or reduced (if' RR < 1.00) compared to the reference
group. Across diabetic and non-diabetic subgroups in Table 3,
evidence of a reduced mortality risk, on average, was observed
for females (RR = 0.88 and 0.76, that is 12 and 24% lower
mortality than males), for blacks (36 and 15% lower mortality
than whites), and for younger patients (2 and 5% increase in
mortality per year of age). Among all patients with a history of
diabetes, statistically significant elevated mortality risks were
associated with the presence of coronary heart disease (RR =
1.20, P = 0.02), congestive heart failure (RR = 1.31, P <0.01),
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Table 3. Proportional hazards, mortality estimates for patient risk factors by presence of diabetes at onset of ESRD, 1986 to 1987 incident
Medicare dialysis patients
Risk factor
Diabetic
(N = 1,725)
Non-diabetic(N = 2,411)
Relative Relative
at onset of ESRD Risk group Reference risk P risk P
Gender Female Male 0.88 0.10 0.76 <0.Ola
Age at ESRD Age 68.7 Age 58.7 1.24 <0.Ola 1.55 <O.Ola
Race (at age 58.7) Black
Other
White
White
0.64
0.81
<0.OIa
0.16
0.85 0.10
0.71 0.11
Race*age Black*68.7 White*68.7 0.64 0.97c 0.73 0.02'
Modality (at age 58.7) CAPD
CCPD
HD
HD
1.26
1.06
0.03
0.82
0.84 0.25
0.96 0.92
Modality*age CAPD*68.7 HD*68.7 l.45' 0.Ilc 0.95 0.20c
Coronary heart disease Present Absent 1.20 0.02 1.11 0.19
Congestive heart failure Present Absent 1.31 <0.01 1.23 <0.01
Cerebrovascular accident Present Absent 1.16 0.14 1.35 <0.01
Peripheral vascular disease Present Absent 1.23 <0.01 1.08 0.46
Neoplasm Present Absent 1.14 0.32 1.62 <0.Ola
Serum albumin gidi 2.5
2.6—3.0
3.1—3.5
>4.0
3.6—4.0
3.6—4.0
3.6—4.0
3.6—4.0
2.27
1.34
1.36
1.00
<0.Ola
<O.0l
<0.0l
0.99
2.07 <o.ola
1.66 <o.oja
1.18 0.05
0.85 0.25
Smoking status: active, or Yes No 1.22 0.06 1.31 <0.01
past history (time unknown)
Obese Yes No 0.95 0.53 0.77 0.03
Physical abilities
Independent ambulating Unable Able 1.20 0.22 0.93 0.65
Independent eating Unable Able 1.07 0.73 1.25 0.34
Independent transferring Unable Able 1.15 0.36 1.12 0.49
Pre-dialysis BUN mg/dl 80 60 1.00 0.94 0.98 0.47
Pre-dialysis serum creatinine 6 9 0.86 <0.Ola 0.91 <0.01
mg/dl
Systolic blood pressure <120 120—159 1.13 0.37 1.54 <0.Ola
mm Hg
160—199
200
120—159
120—159
0.81
1.05
<0.01
0.74
1.19 0.04
1.02 0.92
Missing case mix data Yes No 0.97 0.79 1.01 0.93
ap <0.001
b A white diabetic patient (68.7 years of age) receiving CAPD would have a relative risk of 1.45 compared to a white diabetic patient (68.7 years
of age) on HD. This RR is the product of 1.15*1.26 (interaction RR = 1.15 per 10 years).
P value for interaction with age
and peripheral vascular disease (RR = 1.23, P = 0.01). In a
separate analysis (not presented), lower adjusted mortality was
associated with patients indicating a history of diabetes but with
another medical condition identified as the primary cause of
ESRD (RR = 0.80, P < 0.01) when compared to patients whose
primary cause of ESRD was diabetes.
Among non-diabetic patients, statistically significant elevated
mortality risks were associated with congestive heart failure
(RR = 1.23, P < 0.01), CVA (RR = 1.35, P < 0.01), neoplasm
(RR = 1.62, P < 0.01), and smoking (RR = 1.31, P < 0.01). As
with diabetic patients, statistically significant (P < 0.05) ad-
verse results were associated with serum albumin levels below
3.5 gJdl for non-diabetic patients (2.S gIdl, RR = 2.07; 2.6 to
3.Og/dl, RR = 1.66; 3,1 to 3.5 gIdl, RR = 1.18). In an alternative
model for non-diabetics only, an indicator of undernourished
predicted higher mortality (RR = 1.42, P < 0.01) when exclud-
ing serum albumin and creatinine from the same proportional
hazards model. Analyses for diabetic and non-diabetic patients
combined (not presented) indicated that serum albumin levels
less than 3.5 gldl were predictive of higher mortality in both
CAPD and HD patients (P < 0.01) and may have a steeper risk
gradient in CAPD patients than in HD patients; (2.5 gldl, RR
= 2.82 vs. RR = 2.10) and (2.5 to 3.0 gldl, RR 2.36 vs. RR
1.38).
With adjustment for patient risk factors, the relative mortality
risk for CAPD among non-diabetics was 0.84 (that is, reduced
by 16%) compared to HD at the mean age (58.7 years) of all HD
patients, although this result was not statistically significant
(P = 0.25). Conversely, the selection-adjusted mortality of
CAPD patients was 26% higher overall (RR = 1.26) and
statistically significant (P = 0.03) among diabetic patients at age
58.7. This adjusted relative risk translated to an annual absolute
mortality of approximately 27% for diabetic HD patients and
34% for diabetic CAPD patients. Analysis of the interaction of
age with treatment modality (RR = 1.01 per year, P = 0.11)
yielded a statistically insignificant result that may indicate
elevated mortality risk for CAPD compared to HD that is
accentuated in older diabetic patients. The magnitude of this
effect, if not due to random variation, translated to statistically
significant elevated mortality for CAPD compared to HD
among diabetic patients who were 58 years of age at onset of
ESRD (RR = 1.25, P < 0.05) and 63 years of age (RR = 1.34,
P < 0.01), and for older ages. No statistically significant
difference was found in mortality between the modality groups
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Fig. 1. Proportional hazards estimates of patient survival for CAPD
—
—, N = 310) and HD (—, N = 1,379), incident Medicare patients,
1986—1987. Diabetic patients only. Includes (a) patients with diabetes as
primary cause of ESRD, and (b) patients with a history of diabetes
within ten years prior to onset of ESRD but with another reported
primary cause of ESRD. Survival probabilities were calculated for the
mean of each of the following characteristics: age; race; sex; and mix of
comorbid conditions reported in Table 3. Patients surviving <90 days
were excluded. Sample size for CAPD and HD, respectively, at
one-year follow-up intervals: onset of ESRD, 310, 1379; one year, 177,
994; two years, 63, 626; three years, 27, 247.
fordiabetic patients less than 58 years of age at onset of ESRD
(P> 0.05).
Selection-adjusted patient survival
Stratified CAPD and HD survival curves, estimated using the
Cox proportional hazards model and adjusted for the pre-
treatment risk factors described in Table 3, are presented in
Figure 1 for diabetic patients and in Figure 2 for non-diabetic
patients. Survival probabilities were calculated for the average
patient mix, that is, for the average age, race, sex, and mix of
comorbid factors presented in Table 3. Among non-diabetic
patients, adjusted survival estimates were overall very similar
for CAPD and HD at one year (91.8 and 90.6%, respectively),
two years (78.0 and 78.4%), and through approximately 3.5
years of follow-up. Among diabetic patients, survival was
similar for CAPD and HD at one year (83.3% and 85.4%,
respectively), but was reduced for CAPD relative to HD at two
years (54.0% compared to 64.6% for HD) and through the
remainder of the follow-up period. Proportionality between the
hazard functions for CAPD and HD was evaluated using
graphical techniques, by specifying a time dependent covariate
in a proportional hazards model, and by including a covariate in
the primary model to detect elevated mortality for CAPD after
one year of follow-up. None of these statistical tests identified
a non-proportionality effect for CAPD on diabetic patient
mortality, indicating that the proportional hazards model was
appropriate for these analyses.
Sensitivity analyses
In a separate analysis, not shown, patient mortality was
examined using an intent-to-treat model, which classified a
patient's dialysis modality at one month following ESRD onset
but did not censor at a change in dialysis modality [14]. Under
this alternative specification, the estimated relative mortality
risks for CAPD compared to HD were not materially changed
from the modality history specification presented above. A
recent report from the Michigan Kidney Registry agrees with
the observation that comparisons of CAPD and HD yield
similar results when using a modality history versus an intent-
to-treat assignment of modality [14].
Separate tests were performed on the hypothesis that findings
of higher relative mortality for CAPD among diabetic patients
were confined to a broadly defined group of older patients
whose diabetes was almost exclusively identified as type II
(NIDDM) [15]. Two distinct proportional hazards models, one
for younger (age <50 years) and one for older (age 50 years)
diabetic patients, were specified to test this hypothesis. The
relative mortality risk for older CAPD patients (N =1,312) was
1.34 (P = 0.02), while younger CAPD patients (N = 413) were
found to have a relative risk of 1.11, a result that was not
statistically different from the reference group of younger HD
patients (P = 0.68). Based on the standard errors for the CAPD
relative risk estimates, the relative mortality (CAPD relative to
HD) for the two diabetic age groups was not statistically
different from each other (1.34 was not statistically different
than 1.11).
A third set of mortality analyses considered the validity of
assigning patients with information missing for indicators of
comorbidity to the reference group defined in each case. When
supplementing proportional hazards models with covariates
identifying missing information for each comorbid condition, no
statistically significant association of mortality with "missing
information" covariates was established relative to the refer-
ence value, for any of the conditions. Relative risk estimates for
each comorbid condition were not materially changed by the
method described earlier of assigning missing values to the
mean (for numeric variables) or by regarding the comorbid
condition as not present when medical records did not indicate
whether the condition was present or absent.
DIscussion
The selection of 1986 to 1987 incident ESRD patients for
CAPD and for HD varied according to patient characteristics,
including comorbid conditions present at onset of ESRD, that
were associated with elevated mortality risks. Using estimates
of the relative mortality risk for age, race, and diabetes reported
previously [9—12] and differences in the selection of patients for
CAPD versus HD reported in Table 1, the pre-treatment risk for
CAPD patients compared to HD patients was evaluated. The
unadjusted death rate for HD patients would be expected to be
increased by 18% due to age, while the unadjusted death rate
for CAPD patients would be expected to be increased by 3%
and 2% due to diabetes and race, respectively. The approximate
net effect of differences in age, diabetes, and race was 13%
greater expected mortality risk among patients selected for HD
compared to CAPD, largely because of the on average five-year
age differential between the two treatment groups. The in-
creased mortality risk associated with several comorbid condi-
tions [7] which were found to be more likely present among HD
patients (Table 2) provides further evidence of higher mortality
risk at onset of ESRD for patients selected for HD.
The statistical adjustments made in the current analyses
account for the simultaneous mortality effects of all reported
risk factors. Non-diabetic patients treated with HD revealed
similar adjusted survival outcomes as non-diabetic patients
treated with CAPD. This finding is consistent with reports from
a)>
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0.80
0.60
0.40
0.20
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Spain [4], while Serkes et a! [5] reported results of borderline
statistical significance (RR = 0.62 for CAPD vs. HD, P = 0.08).
In contrast, adjusted mortality comparisons among diabetic
dialysis patients in the current study revealed higher mortality
risk for CAPD patients compared to HD patients (RR 1.26,
P = 0.03). Majorca et al [3] reported a similar elevated mortality
risk for all (that is, diabetic and non-diabetic patients combined)
CAPD compared to all HD patients (RR = 1.35) at the mean age
of 53 years, although statistical significance was not established
(P = 0.16).
The proportional hazards analysis presented in Table 3
contains a statistically insignificant age and modality interaction
effect (P = 0.11 and P = 0.20 for diabetic and non-diabetic
patients, respectively) that corresponds with the specification
used by Majorca et al [3]. Specification of this interaction term
is also consistent with findings from the USRDS of higher
survival for younger incident diabetic patients receiving CAPD
compared to HD and lower survival for older incident diabetic
patients receiving CAPD [1]. Univariate findings of an age effect
on mortality comparisons between CAPD and HD were found
to be particularly strong among prevalent diabetic patients, with
the crossover in CAPD and HD mortality occurring between 40
and 50 years of age [1]. Majorca et al [3] also identified patterns
in mortality between age and treatment modality, although
results indicated worse outcomes for older patients receiving
HD as opposed to CAPD, possibly due to different patterns of
selection between Italy and the U.S. [2].
Results from proportional hazards tests in the current study
indicate an adverse though overall statistically insignificant
effect of increasing age on the relative mortality for CAPD
compared to HD among diabetic patients. Diabetic ESRD
consists of two entities (type I, or IDDM; and type II, or
NIDDM) which identify patients by age, with some overlap.
Cowie et al [15] showed that despite some overlap, age at onset
of ESRD permits a classification of diabetic ESRD since
diabetic patients over age 50 in the U.S. have almost exclu-
sively type II diabetes. Proportional hazards analyses compar-
ing adjusted mortality separately for two broadly defined age
groups (<50 years, 50 years) of diabetics suggest that elevated
mortality for CAPD relative to HD may be accentuated among
older patients. Elevated CAPD mortality associated with in-
creasing age among diabetics (Table 3), if not occurring by
chance, indicates that the relative risk of death is statistically
different by treatment modality among patients 58 years and
older (adverse for CAPD compared to HD). The interaction
effect in Table 3 indicates that adjusted mortality for CAPD and
HD intersected between 40 and 45 years of age, consistent with
previous USRDS mortality analyses for both incident and
prevalent diabetic patients [1].
Thus the present analysis appears to agree with findings from
Michigan [14] that young diabetic patients treated with CAPD
may have a lower mortality risk than corresponding hemodial-
ysis patients. Results from comparative studies that do not
adjust for comorbid conditions [1, 14] may, however, overstate
differences among young diabetic patients according to a recent
USRDS report [2]. This study showed that among diabetics,
younger CAPD patients had a statistically significant lower
count of comorbid conditions than younger HD patients. Thus
the selection of younger diabetic patients with fewer comorbid
conditions to CAPD rather than to HD therapy would partially
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Fig. 2. Proportional hazards estimates of patient survival for CAPD
—
—, N = 371) and HD (—, 1,997), incident Medicare patients, 1986
to 1987. Non-diabetic patients only. Survival probabilities were calcu-
lated for the mean of each of the following characteristics: age; race;
sex; and mix of comorbid conditions reported in Table 3. Patients
surviving <90 days were excluded. Sample size for CAPD and HD,
respectively, at one-year follow-up intervals: onset of ESRD, 371, 1997;
one year, 224, 1455; two years, 109, 995; three years, 55, 471.
explain previous findings of lower mortality for younger CAPD
patients when only limited adjustments were made [1, 14]. The
present study suggests that a reversal of results may occur for
diabetic patients at young ages, although statistical significance
was not observed.
Proportional hazards estimates of diabetic patient survival
adjusted for pre-treatment risk factors (Fig. 1) indicated worse
outcomes for CAPD after one year of therapy, an observation
that may not be detected in studies restricted to one year of
follow-up. Outcomes were similar for diabetic CAPD and HD
patients during the first 12 months of treatment, but the ob-
served higher death rates for CAPD between 12 and 18 months
following onset of ESRD led to lower survival estimates for
CAPD compared to HD during the remainder of the follow-up
period. Tests of proportionality between the hazard functions
for CAPD and HD indicated no statistically significant differ-
ence between adjusted CAPD survival in the short term and the
longer term. Results from two additional proportional hazards
models (not presented) for diabetic patients indicated that
adjusted CAPD mortality was higher after the first year of
ESRD treatment (RR = 1.34, P = 0.04) than mortality observed
from 90 days to one year following first ESRD treatment (RR =
1.14, P 0.47), but was not statistically different. Tests of the
divergence in survival between CAPD and HD indicate that the
null hypothesis, that is, that the relative mortality risk for
CAPD varies over time due to random variation, cannot be
statistically rejected.
Analyses of diabetic patient mortality were also repeated
with an adjustment for the duration of diabetes (in years) prior
to onset of ESRD. No statistically significant evidence of an
association of duration of diabetes with mortality was found
(RR = 1.01 per year with diabetes, P = 0.32), possibly because
comorbidity that increases with duration of diabetes was ad-
justed in this analysis. A lower mortality risk was estimated for
the subgroup of patients with a history of diabetes but with
another identified cause of ESRD (RR = 0.80, P < 0.01)
compared to patients with diabetes as the primary diagnosis.
Results for this subgroup of diabetic patients, which represents
approximately 20 to 30 percent of all patients with a history of
>
Co
C0
0
00
1.00
0.80
0.60
0.40
0.20
Held et a!: CAPD and HD patient mortality 1169
diabetes (note distribution in Table 1), suggest the need for
further study of the severity of diabetes at onset of ESRD for
patients with and without diabetes as the primary diagnosis.
These additional adjustments for the duration and severity of
diabetes at the initiation of renal replacement therapy did not
materially affect, comparisons of CAPD with HD in the short or
longer term.
The graphical pattern of diverging CAPD and HD survival
curves after one year of ESRD treatment can be seen for
diabetic and non-diabetic patients combined in at least two
recent studies [3, 41. The relatively high mortality risk for
diabetic CAPD patients after the first year of therapy suggests
that the protective effect of residual renal function may be lost
in CAPD patients at this stage, while HD patients may have lost
their renal function earlier during the first year [161. Thus,
inadequate dialysis treatment may play a greater role after the
first year of CAPD. However, this speculation would assume
that HD patients received adequate dialysis despite their earlier
loss of residual function. Previous analyses from the USRDS
Case Mix Severity Special Study indicated no statistically
significant relationship between prescribed Kt/V and mortality
(P > 0.10). At least one recent national study has suggested that
inadequate therapy may be responsible for relatively high
mortality among HD patients [17]. The same may be true for
peritoneal dialysis patients even with good peritoneal equilibra-
tion test results, if a large fraction of CAPD patients would
utilize fewer exchanges than prescribed. If underdelivery of
dialysis caused higher mortality for HD and CAPD, proper
adjustment for the delivered dose of dialysis would likely lower
mortality for HD and CAPD. Any existing differences in the
adequacy of delivered dialysis between CAPD and HD may
have affected survival comparisons reported here.
As an alternative explanation, one may consider the role of
unmeasured predictors of outcome at the start of ESRD.
However, mortality risks associated with pre-existing comorbid
conditions of a type or severity that is unmeasured by this
analysis would be expected to have an early rather than late
impact on survival. Clearly, further research will be required to
substantiate current findings and to assess the reasons for an
apparent divergence in survival between CAPD and HD among
diabetic patients.
The current analyses, based on a historical prospective
national study of case mix severity and patient mortality,
cannot assign a cause-and-effect relationship to these observa-
tional data. Mortality comparisons should be viewed with
caution since other unmeasured comorbid factors as well as the
unmeasured severity of reported comorbid factors may not be
distributed evenly between the two treatment groups. Whether
current evidence of higher overall mortality for CAPD relative
to HD among patients with diabetes is a consequence of the
CAPD therapy itself, unmeasured patient selection, residual
renal function, or adequacy of delivered dialysis among incident
diabetic patients will therefore require further study. Adjusted
survival outcomes for non-diabetic patients treated with HD
and CAPD were similar in this large national study.
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